Risk of subsequent prostate cancer in peptic ulcer patients who received helicobacter pylori eradication therapy: an Asian population-based cohort study.
Cohort study
H. pylori
Peptic ulcer
Prostatic cancer
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
31 Aug 2020
31 Aug 2020
Historique:
received:
27
05
2020
accepted:
24
08
2020
entrez:
2
9
2020
pubmed:
2
9
2020
medline:
29
5
2021
Statut:
epublish
Résumé
Studies have shown diverse results regarding the association between H. pylori (HP) infection and the risk of malignancy. There is accumulating evidence relating HP infection to urological diseases. We investigated whether there was an association between HP-infected peptic ulcers and the subsequent risk of prostate cancer. We collected HP-infected male patients from 1998 to 2008 from the Longitudinal Health Insurance Database (LHID). HP-infected patients were identified as those who had a diagnosis of peptic ulcers upon admission and received HP eradication therapy within 1 year after diagnosis. The date of HP infection diagnosis upon admission was defined as the index date. Patients aged < 20 years or with a cancer history were excluded. For each HP-infected patient, we selected four males without peptic ulcers or a history of HP eradication in the LHID for the comparison cohort according to propensity score matching by age, index year, and comorbidity. The risk of prostate cancer and associated risk factors was assessed by Cox proportional hazard regression. A total of 2620 HP infection treatment patients and 10,480 matched comparisons were selected. There were 36 patients in the HP-infected treatment cohort and 117 patients in the comparison cohort with documented prostate cancer development (1.52 and 1.21 per 1000 person-years, respectively). Compared to the comparison cohort, the HP infection cohort had a 1.26-fold increased prostate cancer risk in the Cox models after adjusting for matched-pairs (95% CI = 0.87-1.34). There were no significant differences in subsequent prostate cancer development between HP-infected treatment patients and the comparison cohort. Our findings showed no significant association between HP-infected peptic ulcers and the subsequent risk of prostate cancer. Further studies are warranted to investigate whether this observation is attributable to an HP eradication policy.
Sections du résumé
BACKGROUND
BACKGROUND
Studies have shown diverse results regarding the association between H. pylori (HP) infection and the risk of malignancy. There is accumulating evidence relating HP infection to urological diseases. We investigated whether there was an association between HP-infected peptic ulcers and the subsequent risk of prostate cancer.
METHODS
METHODS
We collected HP-infected male patients from 1998 to 2008 from the Longitudinal Health Insurance Database (LHID). HP-infected patients were identified as those who had a diagnosis of peptic ulcers upon admission and received HP eradication therapy within 1 year after diagnosis. The date of HP infection diagnosis upon admission was defined as the index date. Patients aged < 20 years or with a cancer history were excluded. For each HP-infected patient, we selected four males without peptic ulcers or a history of HP eradication in the LHID for the comparison cohort according to propensity score matching by age, index year, and comorbidity. The risk of prostate cancer and associated risk factors was assessed by Cox proportional hazard regression.
RESULTS
RESULTS
A total of 2620 HP infection treatment patients and 10,480 matched comparisons were selected. There were 36 patients in the HP-infected treatment cohort and 117 patients in the comparison cohort with documented prostate cancer development (1.52 and 1.21 per 1000 person-years, respectively). Compared to the comparison cohort, the HP infection cohort had a 1.26-fold increased prostate cancer risk in the Cox models after adjusting for matched-pairs (95% CI = 0.87-1.34). There were no significant differences in subsequent prostate cancer development between HP-infected treatment patients and the comparison cohort.
CONCLUSION
CONCLUSIONS
Our findings showed no significant association between HP-infected peptic ulcers and the subsequent risk of prostate cancer. Further studies are warranted to investigate whether this observation is attributable to an HP eradication policy.
Identifiants
pubmed: 32867754
doi: 10.1186/s12894-020-00706-2
pii: 10.1186/s12894-020-00706-2
pmc: PMC7461329
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
135Subventions
Organisme : Ministry of Health and Welfare
ID : 109-TDU-B-212-114004
Organisme : MOST Clinical Trial Consortium for Stroke
ID : MOST 108-2321-B-039-003
Références
Am J Epidemiol. 2012 Mar 1;175(5):441-50
pubmed: 22294430
Int J Cardiol. 2015 Dec 15;201:96-101
pubmed: 26292275
J Clin Oncol. 2007 May 10;25(14):1821-3
pubmed: 17488979
Med Hypotheses. 2007;69(5):1160-1
pubmed: 17825999
Cancer Prev Res (Phila). 2016 Dec;9(12):895-905
pubmed: 27913448
Asian Pac J Cancer Prev. 2007 Jul-Sep;8(3):422-8
pubmed: 18159981
Cancer Med. 2018 Oct;7(10):5272-5280
pubmed: 30207080
Urol J. 2015 Sep 04;12(4):2271-5
pubmed: 26341771
Aliment Pharmacol Ther. 1995;9 Suppl 2:59-69
pubmed: 8547530
J Natl Cancer Inst. 2004 Mar 3;96(5):388-96
pubmed: 14996860
Iran J Pathol. 2016 Fall;11(4):323-327
pubmed: 28855923
Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):236-42
pubmed: 21351304
Helicobacter. 2015 Sep;20 Suppl 1:54-61
pubmed: 26372826
J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52
pubmed: 17047193
Arch Intern Med. 2002 Jan 28;162(2):153-60
pubmed: 11802748
Hinyokika Kiyo. 2008 Dec;54(12):783-6
pubmed: 19175002
J Cancer Res Ther. 2016 Oct;12(Supplement):15-18
pubmed: 27721244
Prostate Cancer Prostatic Dis. 2018 Sep;21(3):345-354
pubmed: 29795140
Annu Rev Pathol. 2006;1:63-96
pubmed: 18039108
Nature. 2007 Aug 16;448(7155):767-74
pubmed: 17700693
PLoS One. 2010 Jan 15;5(1):e8736
pubmed: 20090948
J Cancer Res Ther. 2016 Dec;12(Supplement):C229-C232
pubmed: 28230023
J Clin Oncol. 2010 Jun 20;28(18):2952-7
pubmed: 20479409
Cancer Epidemiol. 2014 Aug;38(4):329-38
pubmed: 24986642
Haematologica. 2001 Jun;86(6):609-17
pubmed: 11418369
Cancer Prev Res (Phila). 2008 Oct;1(5):329-38
pubmed: 19138977
Eur J Haematol. 2002 Mar;68(3):187-8
pubmed: 12028368
Curr Urol. 2015 Sep;8(3):138-43
pubmed: 26889133
Histopathology. 2012 Jan;60(1):199-215
pubmed: 22212087
Urol Oncol. 2015 Jun;33(6):266.e17-22
pubmed: 25865574
Cancer. 2000 Aug 1;89(3):630-9
pubmed: 10931463
Alcohol Res. 2015;37(2):311-22
pubmed: 26695753
World J Gastroenterol. 2013 Sep 28;19(36):6098-107
pubmed: 24106412
Lancet Oncol. 2006 Feb;7(2):149-56
pubmed: 16455479
Int J Cancer. 2012 Sep 1;131(5):1210-9
pubmed: 22052329
Helicobacter. 2016 Sep;21 Suppl 1:45-8
pubmed: 27531539
Clin Microbiol Rev. 2006 Jul;19(3):449-90
pubmed: 16847081
Pharmacoepidemiol Drug Saf. 2018 Oct;27(10):1060-1066
pubmed: 28815803
Diabetes Care. 2010 Jul;33(7):1674-85
pubmed: 20587728
Cell Signal. 2014 Nov;26(11):2350-7
pubmed: 25093807
Br J Cancer. 2007 Jan 15;96(1):172-6
pubmed: 17179990
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Helicobacter. 2018 Sep;23 Suppl 1:e12520
pubmed: 30203590
Urol J. 2008 Summer;5(3):139-43
pubmed: 18825618